The U.S. Food and Drug Administration has approved an Abbreviated New Drug Application (ANDA) numbered ANDA085911 for an oral tablet containing 5 mg oxycodone hydrochloride and 500 mg acetaminophen, marketed under the brand name Oxycodone 5/APAP 500.
The product, submitted by Bristol Myers Squibb, received an approval status (AP) on October 25, 1977. FDA records indicate the marketing status is listed as discontinued.
Cập nhật pháp chế19 thg 9, 2026•1 phút đọc
FDA Approves ANDA085911 for Oxycodone 5/APAP 500 Oral Tablet
FDA approved ANDA085911 for an oral tablet containing 5 mg oxycodone and 500 mg acetaminophen, submitted by Bristol Myers Squibb; the product is listed as discontinued.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá